Combination IO (anti-CTLA4 and anti-PD-1) and TT that inhibit BRAF V600 E/K and MEK (known to be mutated in approximately 40-50% of melanoma patients) are effective at treating MBM and prolonging PFS (5, 7, 32–34). Here, CTLA4 is linked to melanoma.